Short and long-term exposure of CNS cell lines to BPA-f a radiosensitizer for Boron Neutron Capture Therapy: Safety dose evaluation by a battery of cytotoxicity tests

NeuroToxicology

Volumn 35, Issue 1, 2013, Pages 84-90

  De Simone, U ^a   Manzo, L ^a   Ferrari, C ^a   Bakeine, J ^a   Locatelli, C ^b   Coccini, T ^a  

^a UNIVERSITY OF PAVIA   (Italy)

^b IRCCS   (Italy)

Author keywords

Boron delivery agent (boronophenylalanine fructose BPA f); Boron Neutron Capture Therapy (BNCT); D384 cells, SH SY5Y cells; In vitro cytotoxicity

Indexed keywords

3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; 4 BORONOPHENYLALANINE; 4 BORONOPHENYLALANINE FRUCTOSE; CALCEIN; FRUCTOSE; PROPIDIUM IODIDE; UNCLASSIFIED DRUG;

ADULT; ARTICLE; ASTROCYTOMA; CANCER CELL CULTURE; CELL ASSAY; CELL DEATH; CELL PROLIFERATION; CELL VIABILITY; CLONOGENIC ASSAY; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; CYTOTOXICITY TEST; FEMALE; FIBROBLAST; HUMAN; HUMAN CELL; NEUROBLASTOMA; NEUTRON CAPTURE THERAPY; PRIORITY JOURNAL; RADIATION DOSE; RADIATION EXPOSURE; RADIATION RESPONSE; RADIATION SAFETY; RISK ASSESSMENT; SENSITIVITY ANALYSIS;

BORON COMPOUNDS; BORON NEUTRON CAPTURE THERAPY; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; FIBROBLASTS; FRUCTOSE; HUMANS; MITOCHONDRIA; NEURONS; RADIATION-SENSITIZING AGENTS; RISK ASSESSMENT; TIME FACTORS; TOXICITY TESTS;

EID: 84872716041     PISSN: 0161813X     EISSN: 18729711     Source Type: Journal    
DOI: 10.1016/j.neuro.2012.12.006     Document Type: Article

References (48)

1. Altieri S., Balzi M., Bortolussi S., Bruschi P., Ciani L., Clerici A.M., et al. Carborane derivatives loaded into liposomes as efficient delivery systems for boron neutron capture therapy. J Med Chem 2009, 52:7829-7835.
2. Aromando R.F., Trivillin V.A., Heber E.M., Pozzi E., Schwint A.E., Itoiz M.E. Early effect of boron neutron capture therapy mediated by boronophenylalanine (BPA-BNCT) on mast cells in premalignant tissue and tumors of the hamster cheek pouch. Oral Oncol 2010, 46:355-359.
3. Bakeine G.J., Di Salvo M., Bortolussi S., Stella S., Bruschi P., Bertolotti P., et al. Feasibility study on the utilization boron neutron capture therapy (BNCT) in rat model of diffuse lung metastases. Appl Radiat Isot 2009, 67:S332-S335.
4. Balmforth A.J., Ball S.G., Freshney R.I., Graham D.I., McNamee H.B., Vaughan P.F. D-1 dopaminergic and beta-adrenergic stimulation of adenylate cyclase in a clone derived from the human astrocytoma cell line G-CCM. J Neurochem 1986, 47:715-719.
5. Barth R.F., Matalka K.Z., Bailey M.Q., Staubus A.E., Soloway A.H., Moeschberger M.L., et al. A nude rat model for neutron capture therapy of human intracerebral melanoma. Int J Radiat Oncol Biol Phys 1994, 28:1079-1088.
6. Barth R.F., Yang W., Rotaru J.H., Moeschberger M.L., Boesel C.P., Soloway A.H., et al. Boron neutron capture therapy of brain tumors: enhanced survival and cure following blood-brain barrier disruption and intracarotid injection of sodium borocaptate and boronophenyalanine. Int J Radiat Oncol Biol Phys 2000, 47:209-218.
7. Barth R.F., Yang W., Bartus R.T., Rotaru J.H., Ferketich A.K., Moeschberger M.L., et al. Neutron capture therapy of intracerebral melanoma: enhanced survival and cure after blood-brain barrier opening to improve delivery of boronophenylalanine. Int J Radiat Oncol Biol Phys 2002, 52:858-868.
8. Barth R.F., Coderre J.A., Vicente M.G.H., Blue T.E. Boron neutron capture therapy of cancer: current status and future prospects. Clin Cancer Res 2005, 11:3987-4002.
9. Campbell W.A., Sah D.E., Medina M.M., Albina J.E., Coleman W.B., Thompson N.L. TA1/LAT-1/CD98 light chain and system L activity, but not 4F2/CD98 heavy chain, respond to arginine availability in rat hepatic Cells. Loss of response in tumor cells. J Biol Chem 2000, 275:5347-5354.
10. Capuani S., Gili T., Bozzali M., Russo S., Porcari P., Cametti C., et al. Boronophenylalanine uptake in C6 glioma model is dramatically increased by l-DOPA preloading. Appl Radiat Isot 2009, 67:S34-S36.
11. Coderre JA, Bergland R, Chada M, Bergland R, Chada M, Chamana AD, et al. Boron neutron capture therapy of glioblastoma multiform using the p-borophenylalanine-fructose complex and epithermal neutrons. In: Mishima Y, Ed. Neutron capture therapy for cancer. Plenum Press, New York; 1996: p. 553-61.
12. Coderre J.A., Chanana A.D., Joel D.D., Elowitz E.H., Micca P.L., Nawrocky M.M., et al. Biodistribution of boronophenylalanine in patients with glioblastoma multiforme: boron concentration correlates with tumor cellularity. Radiat Res 1998, 149:163-170.
13. Dagrosa M.A., Viaggi M., Rebagliati R.J., Batistoni D., Kahl S.B., Juvenal G.J., et al. Biodistribution of boron compounds in an animal model of human undifferentiated thyroid cancer for boron neutron capture therapy. Mol Pharm 2005, 2:151-156.
14. Dagrosa A., Carpano M., Perona M., Thomasz L., Nievas S., Cabrini R., et al. Studies for the application of boron neutron capture therapy to the treatment of differentiated thyroid cancer. Appl Radiat Isot 2011, 69:1752-1755.
15. Detta A., Cruickshank G.S. l-amino acid transporter-1 and boronophenylalanine-based boron neutron capture therapy of human brain tumors. Cancer Res 2009, 69:2126-2132.
16. Diaz A.Z. Assessment of the results from the phase I/II boron neutron capture therapy trials at the Brookhaven National Laboratory from a clinician's point of view. J Neurooncol 2003, 62:101-109.
17. Elmore S. Apoptosis: a review of programmed cell death. Toxicol Pathol 2007, 35:495-516.
18. Ferrari C., Zonta C., Cansolino L., Clerici A.M., Gaspari A., Altieri S., et al. Selective uptake of p-boronophenylalanine by osteosarcoma cells for boron neutron capture therapy. Appl Radiat Isot 2009, 67:S341-S344.
19. Fujimoto T., Andoh T., Sudo T., Fujita I., Imabori M., Moritake H., et al. Evaluation of BPA uptake in clear cell sarcoma (CCS) in vitro and development of an in vivo model of CCS for BNCT studies. Appl Radiat Isot 2011, 69:1713-1716.
20. Golstein P., Kroemer G. Cell death by necrosis: towards a molecolr definition. Trends Biochem Sci 2007, 32:37-43.
21. Gonzàlez S.J., Bonomi M.R., Santa Cruz G.A., Blaumann H.R., Calzetta Larrieu O.A., Menéndez P., et al. First BNCT treatment of a skin melanoma in Argentina: dosimetric analysis and clinical outcome. Appl Radiat Isot 2004, 61:1101-1105.
22. Henriksson R., Capala J., Michanek A., Lindahl S.A., Salford L.G., Franzén L., et al. Swedish Brain Tumour Study Group. Boron neutron capture therapy (BNCT) for glioblastoma multiforme: a phase II study evaluating a prolungate high-dose of boronophenylalanine (BPA). Radiother Oncol 2008, 88:183-191.
23. Herzog E., Casey A., Lyng F.M., Chambers G., Byrne H.J., Davoren M. A new approach to the toxicity testing of carbon-based nanomaterials - the clonogenic assay. Toxicol Lett 2007, 174:49-60.
24. Joel D.D., Coderre J.A., Micca P.L., Nawrocky M.M. Effect of dose and infusion time on the delivery of p-boronophenylalanine for neutron capture therapy. J Neurooncol 1999, 41:213-221.
25. Joensuu H., Kankaanranta L., Seppälä T., Auterinen I., Kallio M., Kulvik M., et al. Boron neutron capture therapy of brain tumors: clinical trials at the Finnish facility using boronophenylalanine. J Neurooncol 2003, 62:123-134.
26. Jun Y.J., Jadhav V.B., Min J.H., Cui J.X., Chae S.W., Choi J.M., et al. Stable and efficient delivery of docetaxel by micelle-encapsulation using a tripodal cyclotriphosphazene amphiphile. Int J Pharm 2012, 422:374-380.
27. Kabalka G.W., Yao M.L., Marepally S.R., Chandra S. Biological evaluation of boronated unnatural amino acids as new boron carriers. Appl Radiat Isot 2009, 67:S374-S379.
28. Kageji T., Mizobuchi Y., Nagahiro S., Nakagawa Y., Kumada H. Clinical results of boron neutron capture therapy (BNCT) for glioblastoma. Appl Radiat Isot 2011, 69:1823-1825.
29. Kankaanranta L., Seppälä T., Koivunoro H., Välimäki P., Beule A., Collan J., et al. l-Boronophenylalanine-mediated boron neutron capture therapy for malignant glioma progressing after external beam radiation therapy: a phase I study. Int J Radiat Oncol Biol Phys 2011, 80:369-376.
30. Kankaanranta L., Seppälä T., Koivunoro H., Saarilahti K., Atula T., Collan J., et al. Boron neutron capture therapy in the treatment of locally recurred head-and-neck cancer: final analysis of a phase I/II trial. Int J Rad Oncol Biol Phys 2012, 82:e67-e75.
31. Kato I., Fujita Y., Maruhashi A., Kumada H., Ohmae M., Kirihata M., et al. Effectiveness of boron neutron capture therapy for recurrent head and neck malignancies. Appl Radiat Isot 2009, 67:S37-S42.
32. Lu C., Liu P. Effect of chitosan multilayers encapsulation on controlled release performance of drug-loaded superparamagnetic alginate nanoparticles. J Mater Sci Mater 2012, 23:393-398.
33. Mignotte B., Vayssiere J.L. Mithocondria and apoptosis. Eur J. Biochem 1998, 252:1-15.
34. 10B molecule-melanoma cell interaction from in vitro to first clinical trial. Pigment Cell Res 1989, 2:226-234.
35. 10B-compound. Lancet 1989, 2:388-389.
36. Nakagawa Y., Pooh K., Kobayashi T., Kageji T., Uyama S., Matsumura A., et al. Clinical review of the Japanese experience with boron neutron capture therapy and a proposed strategy using epithermal neutron beams. J Neurooncol 2003, 62:87-99.
37. Papaspyrou M., Feinendegen E.L., Müller-Gärtner H.W. Preloading with l-tyrosine increases the uptake of boronophenylalanine in mouse melanoma cells. Cancer Res 1994, 54:6311-6314.
38. Pisarev M.A., Dagrosa M.A., Juvenal G.J. Boron neutron capture therapy in cancer: past, present and future. Arq Bras Endocrinol Metab 2007, 51:852-856.
39. Richard J.L. Sax's dangerous properties of industrial materials, 3 volume book set 2004, John Wiley & Sons, Inc., New York. 11th ed.
40. Sekhon B.S. Boron neutron capture therapy - an overview. Pharmaceutical Reviews 2008, 6:2.
41. 10B from p-boronophenylalanine in a brain tumor model for boron neutron capture therapy. Cancer Res 1996, 56:4302-4306.
42. Smith D.R., Chandra S., Barth R.F., Yang W., Joel D.D., Coderre J.A. Quantitative imaging and microlocalization of boron-10 in brain tumors and infiltrating tumor cells by SIMS ion microscopy: relevance to neutron capture therapy. Cancer Res 2001, 61:8179-8187.
43. Suzuki M., Sakurai Y., Masunaga S., Kinashi Y., Nagata K., Maruhashi A., et al. Feasibility of boron neutron capture therapy (BNCT) for malignant pleural mesothelioma from a viewpoint of dose distribution analysis. Int J Radiat Oncol Biol Phys 2006, 66:1584-1589.
44. Trembley J.H., Unger G.M., Korman V.L., Tobolt D.K., Kazimierczuk Z., Pinna L.A., et al. Nanoencapsulated anti-CK2 small molecule drug or siRNA specifically targets malignant cancer but not benign cells. Cancer Lett 2012, 315:48-58.
45. Wittig A., Sauerwein W.A., Coderre J.A. Mechanisms of transport of p-borono-phenylalanine through the cell membrane in vitro. Radiat Res 2000, 153:173-180.
46. Wolf D.A., Wang S., Panzica M.A., Bassily N.H., Thompson N.L. Expression of a highly conserved oncofetal gene, TA1/E16, in human colon carcinoma and other primary cancers: homology to Schistsoma masoni amino acid permease and Caenorhabditis elegans gene products. Cancer Res 1996, 56:5012-5022.
47. Yasui L., Kroc T., Gladden S., Andorf C., Bux S., Hosmane N. Boron neutron capture in prostate cancer cells. Appl Radiat Isot 2012, 70:6-12.
48. Zonta A., Pinelli T., Prati U., Roveda L., Ferrari C., Clerici A.M., et al. Extra-corporeal liver BNCT for the treatment of diffuse metastases: what was learned and what is still to be learned. Appl Radiat Isot 2009, 67:S67-S75.